beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
![BeyondSpring logo](/files/LOGO/1677940-BYSI.png)
Company profile
Ticker
BYSI
Exchange
Website
CEO
Lan Huang
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
BYSI stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Jul 24
F-3/A
Shelf registration (foreign) (amended)
2 Jul 24
F-3
Shelf registration (foreign)
12 Jun 24
6-K
Current report (foreign)
12 Jun 24
424B5
Prospectus supplement for primary offering
12 Jun 24
20-F
2023 FY
Annual report (foreign)
29 Apr 24
6-K
Current report (foreign)
18 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
2 Feb 24
6-K
Current report (foreign)
16 Jan 24
Latest ownership filings
SC 13G/A
Ever Regal Group Ltd
14 Feb 24
SC 13G/A
Ever Regal Group Ltd
7 Apr 23
SC 13G/A
Ever Regal Group Ltd
14 Feb 23
SC 13G/A
ALLIANCEBERNSTEIN L.P.
14 Feb 22
SC 13G
Decheng Capital Management III (Cayman), LLC
14 Feb 22
SC 13G/A
Shenzhen Sangel Capital Management Ltd Co
14 Feb 22
SC 13G/A
Ever Regal Group Ltd
11 Feb 22
SC 13G/A
Ever Regal Group Ltd
16 Feb 21
SC 13G
ALLIANCEBERNSTEIN L.P.
8 Feb 21
SC 13D/A
Decheng Capital China Life Sciences USD Fund III, L.P.
8 Dec 20
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
20.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 25.89 mm |
Total shares | 7.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ever Regal | 4.62 mm | $0.00 |
Decheng Capital China Life Sciences USD Fund III | 1.98 mm | $20.21 mm |
Shenzhen Sangel Capital Management | 1.25 mm | $5.68 mm |